Header Logo

Connection

KEVIN GAREY to Clostridium Infections

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Clostridium Infections.
KEVIN GAREY
Connection Strength
26.543
Clostridium Infections
  1. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
    View in: PubMed
    Score: 0.710
  2. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.705
  3. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence. Clin Infect Dis. 2023 12 05; 77(Suppl 6):S487-S496.
    View in: PubMed
    Score: 0.700
  4. Emerging Options for the Prevention and Management of Clostridioides difficile Infection. Drugs. 2023 Feb; 83(2):105-116.
    View in: PubMed
    Score: 0.659
  5. Nonmammalian models to study Clostridioides difficile infection; a systematic review. Anaerobe. 2023 Feb; 79:102694.
    View in: PubMed
    Score: 0.658
  6. Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2253570.
    View in: PubMed
    Score: 0.657
  7. Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies. Gut Microbes. 2023 Jan-Dec; 15(1):2223345.
    View in: PubMed
    Score: 0.657
  8. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 09 30; 75(7):1164-1170.
    View in: PubMed
    Score: 0.645
  9. Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers. Anaerobe. 2022 Oct; 77:102617.
    View in: PubMed
    Score: 0.639
  10. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0224421.
    View in: PubMed
    Score: 0.635
  11. Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence. Ann Pharmacother. 2023 02; 57(2):184-192.
    View in: PubMed
    Score: 0.631
  12. Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings. Anaerobe. 2022 Jun; 75:102543.
    View in: PubMed
    Score: 0.619
  13. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med. 2022 02; 43(1):28-38.
    View in: PubMed
    Score: 0.618
  14. Antibiotic Therapies for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc. 2021 Nov 17; 10(Supplement_3):S52-S57.
    View in: PubMed
    Score: 0.608
  15. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
    View in: PubMed
    Score: 0.598
  16. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
    View in: PubMed
    Score: 0.588
  17. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol. 2021 01; 37(1):30-36.
    View in: PubMed
    Score: 0.572
  18. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
    View in: PubMed
    Score: 0.569
  19. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis. 2020 08 22; 71(5):1140-1141.
    View in: PubMed
    Score: 0.558
  20. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
    View in: PubMed
    Score: 0.538
  21. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr; 62:102142.
    View in: PubMed
    Score: 0.532
  22. Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
    View in: PubMed
    Score: 0.518
  23. Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. Anaerobe. 2019 Oct; 59:107-111.
    View in: PubMed
    Score: 0.514
  24. Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clin Infect Dis. 2019 05 17; 68(11):1887-1893.
    View in: PubMed
    Score: 0.511
  25. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.476
  26. Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.445
  27. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul; 93(3):286-9.
    View in: PubMed
    Score: 0.413
  28. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov; 36(11):1318-23.
    View in: PubMed
    Score: 0.394
  29. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. PLoS One. 2014; 9(7):e102848.
    View in: PubMed
    Score: 0.366
  30. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep; 85(1):28-32.
    View in: PubMed
    Score: 0.340
  31. Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. J Hosp Infect. 2013 Apr; 83(4):294-9.
    View in: PubMed
    Score: 0.332
  32. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci. 2012 Apr; 343(4):277-80.
    View in: PubMed
    Score: 0.312
  33. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec; 66(12):2850-5.
    View in: PubMed
    Score: 0.301
  34. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J Hosp Infect. 2011 Sep; 79(1):23-6.
    View in: PubMed
    Score: 0.295
  35. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol. 2010 Aug; 5(8):1153-6.
    View in: PubMed
    Score: 0.278
  36. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010 May; 8(5):555-64.
    View in: PubMed
    Score: 0.273
  37. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010 Apr; 74(4):309-18.
    View in: PubMed
    Score: 0.269
  38. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol. 2009 Jan; 43(1):91-3.
    View in: PubMed
    Score: 0.249
  39. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008 Oct; 70(2):142-7.
    View in: PubMed
    Score: 0.243
  40. A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
    View in: PubMed
    Score: 0.188
  41. Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites. Antimicrob Agents Chemother. 2024 Dec 05; 68(12):e0120624.
    View in: PubMed
    Score: 0.187
  42. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response. Clin Infect Dis. 2024 07 19; 79(1):15-21.
    View in: PubMed
    Score: 0.183
  43. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.182
  44. Microscopy methods for Clostridioides difficile. Anaerobe. 2024 Apr; 86:102822.
    View in: PubMed
    Score: 0.177
  45. Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatr Infect Dis J. 2024 Feb 01; 43(2):136-141.
    View in: PubMed
    Score: 0.176
  46. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0034923.
    View in: PubMed
    Score: 0.173
  47. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. NPJ Biofilms Microbiomes. 2023 08 03; 9(1):54.
    View in: PubMed
    Score: 0.171
  48. The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
    View in: PubMed
    Score: 0.168
  49. Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. Lancet Infect Dis. 2023 07; 23(7):e259-e265.
    View in: PubMed
    Score: 0.167
  50. Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial. Clin Infect Dis. 2023 02 08; 76(3):e1195-e1201.
    View in: PubMed
    Score: 0.165
  51. Stool Interleukin-1? Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clin Infect Dis. 2023 02 08; 76(3):e1467-e1475.
    View in: PubMed
    Score: 0.165
  52. Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2023 09; 44(9):1403-1409.
    View in: PubMed
    Score: 0.164
  53. Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection. Clin Infect Dis. 2022 11 30; 75(11):2019-2022.
    View in: PubMed
    Score: 0.163
  54. Stool Toxin Concentration Does Not Distinguish Clostridioides difficile Infection from Colonization in Children Less Than 3 Years of Age. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):454-458.
    View in: PubMed
    Score: 0.162
  55. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection. Clin Infect Dis. 2022 07 06; 74(12):2142-2149.
    View in: PubMed
    Score: 0.159
  56. Colitis caused by Clostridioides difficile infection in a domestic dog: A case report. Anaerobe. 2022 Feb; 73:102511.
    View in: PubMed
    Score: 0.153
  57. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2022 10; 43(10):1339-1344.
    View in: PubMed
    Score: 0.151
  58. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):e1029-e1044.
    View in: PubMed
    Score: 0.150
  59. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 09 07; 73(5):755-757.
    View in: PubMed
    Score: 0.150
  60. The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. J Clin Microbiol. 2021 08 18; 59(9):e0058521.
    View in: PubMed
    Score: 0.149
  61. A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021 06; 7(6).
    View in: PubMed
    Score: 0.147
  62. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis. 2021 05 18; 72(10):e460-e465.
    View in: PubMed
    Score: 0.147
  63. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe. 2021 Jun; 69:102352.
    View in: PubMed
    Score: 0.144
  64. Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18.
    View in: PubMed
    Score: 0.143
  65. Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. Gastroenterology. 2021 03; 160(4):1301-1314.e8.
    View in: PubMed
    Score: 0.142
  66. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2021 10; 66(10):3303-3306.
    View in: PubMed
    Score: 0.142
  67. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.140
  68. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020 05 01; 318(5):G870-G888.
    View in: PubMed
    Score: 0.136
  69. Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe. 2019 Aug; 58:22-29.
    View in: PubMed
    Score: 0.128
  70. Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs. 2019 Apr; 28(4):303-310.
    View in: PubMed
    Score: 0.126
  71. Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
    View in: PubMed
    Score: 0.126
  72. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.125
  73. Reply to Fabre et al. Clin Infect Dis. 2018 11 28; 67(12):1958-1959.
    View in: PubMed
    Score: 0.124
  74. Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
    View in: PubMed
    Score: 0.122
  75. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 03 19; 66(7):e1-e48.
    View in: PubMed
    Score: 0.118
  76. Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018 Nov; 24(11):1190-1194.
    View in: PubMed
    Score: 0.117
  77. Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. Clin Vaccine Immunol. 2017 Aug; 24(8).
    View in: PubMed
    Score: 0.113
  78. Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
    View in: PubMed
    Score: 0.110
  79. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
    View in: PubMed
    Score: 0.108
  80. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 09; 50(8):631-7.
    View in: PubMed
    Score: 0.106
  81. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
    View in: PubMed
    Score: 0.104
  82. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.103
  83. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015; 10(4):e0123405.
    View in: PubMed
    Score: 0.096
  84. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015 Apr; 53(4):1192-7.
    View in: PubMed
    Score: 0.095
  85. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
    View in: PubMed
    Score: 0.088
  86. Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr; 56(7):1059-60.
    View in: PubMed
    Score: 0.082
  87. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection. J Hosp Infect. 2011 Feb; 77(2):172-3.
    View in: PubMed
    Score: 0.071
  88. Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. Pharm World Sci. 2009 Oct; 31(5):565.
    View in: PubMed
    Score: 0.065
  89. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis. 2008 Oct; 21(5):500-7.
    View in: PubMed
    Score: 0.061
  90. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
    View in: PubMed
    Score: 0.054
  91. Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 12 20; 64(1).
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.